Indication
cervical cancer
8 clinical trials
15 products
4 drugs
Product
Bevacizumab Biosimilar MB02Clinical trial
Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican PopulationStatus: Recruiting, Estimated PCD: 2024-02-20
Product
BevacizumabClinical trial
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Product
AK104Clinical trial
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)Status: Withdrawn, Estimated PCD: 2021-10-22
Product
TopotecanProduct
GemcitabineProduct
BalstilimabProduct
VinorelbineProduct
IrinotecanProduct
PemetrexedClinical trial
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Product
PembrolizumabProduct
LenvatinibClinical trial
A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical CancerStatus: Recruiting, Estimated PCD: 2026-02-01
Drug
AtezolizumabProduct
CobolimabClinical trial
SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II StudyStatus: Completed, Estimated PCD: 2020-04-30
Product
SHR-1210Product
ApatinibClinical trial
A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic CancerStatus: Terminated, Estimated PCD: 2022-07-15
Drug
AN0025Product
TremelimumabClinical trial
A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyStatus: Withdrawn, Estimated PCD: 2023-06-01
Drug
PD-1 antibodyDrug
Sitravatinib